FARMINGDALE, N.Y., April 1 /PRNewswire-FirstCall/ -- Misonix, Inc.
(Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device
technology, which in Europe is used for the ablation of tumors and worldwide
for other acute health conditions, has entered into a new, three year,
exclusive distribution agreement with Sophysa Benelux, based in Braine
l'Alleud, Belgium, for the distribution of the SonaStar(TM) Ultrasonic
Surgical Aspirator and the BoneScalpel(TM) Ultrasonic Bone Cutter.
The agreement provides Sophysa with the rights to sell in Belgium and
Luxembourg, and includes minimum purchase requirements.
Sophysa is acknowledged as a market leader and has built a reputation as a
distributor of state-of-the-art medical devices and capital equipment, with
special emphasis in neuro and spine surgery.
The SonaStar is used by Neuro and General Surgeons for quick and efficient
removal of both hard and soft tumors while sparing most vessels. In addition,
OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to
safely remove osseous structures, thus providing access to the surgical site.
The BoneScalpel is a tissue specific osteotomy device capable of making
precise cuts through bone and hard tissue while largely preserving delicate
soft tissue structures. It offers the convenience and speed of a power
instrument without the potential hazards associated with rotary sharps.
"Misonix welcomes Sophysa Benelux to our growing sales and distribution
organization. We know Sophysa as a first tier distributor of advanced medical
equipment in the Benelux countries," said Michael A. McManus, Jr., President
and Chief Executive Officer of Misonix. "Sophysa has established themselves as
a quality distribution partner for successfully introducing high tech medical
devices to their markets. We are particularly pleased that they will be
distributing two of our product platforms through their well established
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets
therapeutic ultrasonic medical devices and laboratory equipment. Misonix's
therapeutic ultrasonic platform is the basis for several innovative medical
technologies. Addressing a combined market estimated to be in excess of $3
billion annually; Misonix's proprietary ultrasonic medical devices are used
for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery,
and other surgical and medical applications. Additional information is
available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press
release, content herein may contain "forward-looking statements" that are made
pursuant to the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These statements are based on management's current
expectations and are subject to uncertainty and changes in circumstances.
Investors are cautioned that forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from the
statements made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks associated with
international sales and currency fluctuations, uncertainties as a result of
research and development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying levels of
statistical relevancy, risks involved in introducing and marketing new
products, potential acquisitions, consumer and industry acceptance, litigation
and/or court proceedings, including the timing and monetary requirements of
such activities, the timing of finding strategic partners and implementing
such relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.
Investor Relations Contact:
Cameron Associates, Inc.
SOURCE Misonix, Inc.